In clinical cohorts, the correlations between high or low expression levels of CDKN1A and BCAT2 genes and other laboratory parameters including serum iron and ferritin concentration, and disease progression or treatment resistance of MM patients were observed through a long‐term follow‐up study. This evidence concerns the gene BCAT2 and Miyoshi myopathy.